Massive study tests PCV20 Vaccine's power to stop pneumonia in At-Risk adults
NCT ID NCT07251465
First seen Jan 05, 2026 · Last updated May 15, 2026 · Updated 25 times
Summary
This study looks at health records of over 800,000 adults to see how well the PCV20 vaccine prevents pneumonia and other lung infections. It focuses on people aged 18 and older who have a higher risk of getting pneumococcal disease. The goal is to compare pneumonia rates between those who received the vaccine and those who did not, using existing electronic health data.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PNEUMONIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer
New York, New York, 10001, United States
Conditions
Explore the condition pages connected to this study.